CD28 and neoplasm: In vivo mouse tumour models, compared with anti-CLDN18.2, anti-CLDN18.2-anti-CD28 showed a greater increase in the percentage of CD8+ T cells and higher expression of CD69 on CD8+ T cells in tumour tissues as well as a greater reduction in tumour burden.